Quantcast

Latest Zidovudine Stories

2014-07-17 04:20:56

GENEVA, July 17, 2014 /PRNewswire/ -- MPP forges first agreement with a Chinese manufacturer Desano; and with Cipla, Mylan and Micro Labs; Extends Collaborations with Aurobindo, Laurus Labs and Emcure Three days before the start of the 20th International AIDS Conference in Melbourne, Australia, the Medicines Patent Pool (MPP) announced seven new sub-licensing agreements for the manufacture of generic HIV medicines, atazanavir (ATV) and dolutegravir (DTG). The...

2014-07-11 10:26:38

Emory Health Sciences Viral fitness tracks with likelihood of transmission New research on HIV transmission shows that viral fitness is an important basis of a "genetic bottleneck" imposed every time a new person is infected. The findings define a window of opportunity for drugs or vaccines to prevent or limit infection. HIV represents evolution on overdrive. Every infected individual contains a swarm of viruses that exhibit variability in their RNA sequence, and new mutations are...

Child Believed To Be Cured Of HIV Now Has Detectable Virus Levels
2014-07-11 07:38:26

redOrbit Staff & Wire Reports - Your Universe Online The Mississippi infant believed to have been cured of HIV following an extended remission now once again has “detectable levels” of the AIDS-causing virus in her blood, the US National Institute of Allergy and Infectious Diseases (NIAID) has confirmed. The child was born prematurely in 2010 to an HIV-infected mother who had not been diagnosed until the time of delivery and had not been given antiretroviral medication during...

2014-07-01 10:07:43

University of Pennsylvania School of Medicine Lack of clinical trial data, guidelines on HIV patients with cancer may contribute to health disparity HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a new, large retrospective study from researchers in Penn Medicine's Abramson Cancer Center and the National Cancer Institute (NCI) published online ahead of print in the Journal...

2014-06-30 11:45:29

New York University HIV and its transmission has long been associated with injecting drug use, where hypodermic syringes are used to administer illicit drugs. Now, a newly reported study by researchers affiliated with New York University's Center for Drug Use and HIV Research (CDUHR) in the journal PLOS ONE, shows that HIV infection among heterosexual non-injecting drug users (no hypodermic syringe is used; drugs are taken orally or nasally) in New York City (NYC) has now surpassed HIV...

2014-06-28 09:23:51

University of Pittsburgh Schools of the Health Sciences While bringing new drugs to market is important for increasing life expectancy in younger people with HIV, lowering the toxicity of those drugs may have an even greater health impact on all HIV patients, a University of Pittsburgh Graduate School of Public Health analysis reveals. The research, supported by the National Science Foundation (NSF) and National Institutes of Health (NIH), and published June 25 in the journal PLOS ONE,...

2014-06-24 08:32:27

OAKLAND, Calif., June 24, 2014 /PRNewswire/ -- A 15-year study found that HIV-positive individuals had a 40 percent increased risk of ischemic stroke, however stroke rates were nearly the same for HIV-positive individuals with high CD4 cell counts as for HIV-negative subjects. http://photos.prnewswire.com/prnvar/20130718/SF49717LOGO The study, published recently in AIDS, the official journal of the International AIDS Society, covered the years 1996 through 2011 and included nearly...

2014-06-12 08:28:17

Agreement is ViiV Healthcare's first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine LONDON, June 12, 2014 /PRNewswire/ -- ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland Ltd (Janssen) for the development and commercialisation of a single-tablet combining dolutegravir (Tivicay®) and Janssen's non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant®([1])). This...

2014-06-12 08:28:09

CORK, Ireland, June 12, 2014 /PRNewswire/ -- Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT(R)) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY(R)) as the sole active ingredients for the maintenance treatment of people living with Human...

2014-06-10 08:29:37

Key findings point to significant differences between treated and untreated people living with HIV RESEARCH TRIANGLE PARK, N.C., June 10, 2014 /PRNewswire/ -- ViiV Healthcare today announced new survey data that provide important insights that may help explain why HIV treatment rates remain low in the United States. Findings from the online survey, conducted by Harris Interactive on behalf of ViiV Healthcare in 2013, reveal gaps in knowledge about HIV and its treatment among diagnosed but...


Latest Zidovudine Reference Libraries

0_a4499f7c8759b5cbe79bad5eca319070
2011-01-26 14:08:59

Human immunodeficiency virus (HIV), a lentivirus, causes acquired immunodeficiency syndrome (AIDS) which is a condition in humans were the immune system begins to fail, leading to life-threatening opportunistic infections. Infection is transferred through bodily fluids where HIV is present as both free virus particles and within infected immune cells. The four most common routes of infection are unsafe sex, contaminated needles, breast milk, and transmission from an infected mother to her...

More Articles (1 articles) »
Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.